NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) (As of 10/3/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrends About Aravive Stock (NASDAQ:ARAV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aravive alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage Volume4.25 million shsMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Read More… Retire off just one stock ticker? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Aravive Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks15th Percentile Overall ScoreARAV MarketRank™: Aravive scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aravive.Read more about Aravive's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAravive has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aravive's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ARAV. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAravive does not currently pay a dividend.Dividend GrowthAravive does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.77 Short InterestThere is no current short interest data available for ARAV. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Aravive this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aravive insiders have not sold or bought any company stock.Percentage Held by Insiders60.40% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.80% of the stock of Aravive is held by institutions.Read more about Aravive's insider trading history. Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Stock News HeadlinesHouston-based health supplements co. to delist from Nasdaq, dissolveOctober 3 at 3:09 PM | bizjournals.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.com44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.October 3, 2024 | InvestorPlace (Ad)Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightApril 2, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares SlideJanuary 18, 2024 | msn.comWhy Is Nuvve (NVVE) Stock Down 31% Today?January 18, 2024 | msn.comWhy Is Aravive (ARAV) Stock Down 52% Today?January 18, 2024 | markets.businessinsider.comSee More Headlines ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? Aravive's stock was trading at $0.1237 on January 1st, 2024. Since then, ARAV stock has decreased by 67.6% and is now trading at $0.0401. View the best growth stocks for 2024 here. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The business earned $2.41 million during the quarter, compared to the consensus estimate of $2.36 million. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings10/27/2021Today10/03/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.99 million Price / Sales0.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.22Miscellaneous Outstanding Shares73,563,000Free Float29,131,000Market Cap$2.95 million OptionableNo Data Beta2.19 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ARAV) was last updated on 10/3/2024 by MarketBeat.com Staff From Our PartnersThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.